Drug Type Small molecule drug |
Synonyms Ecabet, Ecabet Sodium, Ecabet Sodium Granules + [7] |
Target- |
Mechanism Urease inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Oct 1993), |
Regulation- |
Molecular FormulaC20H28NaO5S |
InChIKeyJNTMHWBQZJIWMT-YGJXXQMASA-N |
CAS Registry86408-72-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute gastritis | JP | 22 Nov 1995 | |
Chronic gastritis | JP | 22 Nov 1995 | |
Stomach Ulcer | JP | 01 Oct 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 3 | JP | - | |
Dry Eye Syndromes | Phase 2 | US | - | |
Dry Eye Syndromes | Phase 2 | JP | - |
Phase 2 | 183 | (Ecabet Ophthalmic Solution) | nxclrhwbrj(akvpmhyefv) = cfcknsaewa fqyfbqeznc (tqwvicpkhn, cshpraovua - twkwloioyi) View more | - | 03 Sep 2020 | ||
placebo (Vehicle) | nxclrhwbrj(akvpmhyefv) = mofbjuvjcu fqyfbqeznc (tqwvicpkhn, kwbbqowtie - mnjhuuzphi) View more |